On 23 December – Cessatech A/S (“Cessatech” or “the Company”) gives an update on the major milestones for the coming year. We are very pleased with the progress Cessatech has made during 2024, and this is truly the result of an incredible team-effort and partnership collaborations.

During 2024 we closed the agreement with Proveca for the commercialization of CT001 – and this was proof that our business model is working; to provide paediatric solutions where there is a large unmet need. During the next years we want more products in development, through partnerships in Europe and with more involvement in the US. Some of the important milestones anticipated for 2025 include:

• The US launch has been delayed, mainly due to manufacturing issues – and we believe this has almost been solved, and hence anticipate launch during 1H 2025, more details will follow soon.
• The paediatric study 0202 is coming to an end, and we anticipate having last patient in the beginning of 2025. We are very excited about this study and hope to present good results from CT001 in children.
• Together with Proveca, we will initiate the regulatory EMA submission for CT001, this also includes the Notify Body process for medical devices. 
• In 2025 we will also work hard for new partnerships, look for new opportunities and get moving with CT002.

Jes Trygved, CEO, Cessatech
As the year 2024 is coming to an end, we want to reflect on the accomplishments during the year and focus on the milestones in progress. We have a great year ahead and look forward to communicating more in detail on the above listed important topics in the year to come.

For more information about Cessatech, please contact:
Jes Trygved, CEO
Phone: +45 9387 2309
E-mail: jes.trygved@cessatech.com
www.cessatech.com

About Cessatech
Cessatech A/S is a Danish pharmaceutical company committed to developing and commercializing evidence-based and innovative medicines for children for the treatment of paediatric acute pain. Its lead asset (CT001) is an analgesic nasal spray for the treatment of acute and planned painful procedures in children. The advantages include needle-free administration, easy administration, a fast-acting therapeutic effect, and being medically approved for children. CT001 is at its pivotal stage of clinical development, and CT002 is at the early development phase.